文献速递精神分裂症与精神病性障碍物质与行为成瘾

抗精神病药使用、物质使用与精神分裂症复发风险的全国队列关联分析

Associations between antipsychotic use, substance use and relapse risk in patients with schizophrenia: real-world evidence from two national cohorts.
PubMed 文献 · Br J Psychiatry · 2022-01-01

两项全国队列(芬兰N=45 476随访22年,瑞典随访11年)比较抗精神病药在精神分裂症患者中预防首次物质使用障碍(SUD)及降低精神科和SUD相关入院风险的真实世界效果。氯喹平与抗精神病药联合治疗与最低的SUD发生风险及复发风险相关,两国结果一致。

要点

  • 无SUD的精神分裂症患者中,氯喹平使用与最低的首次SUD发生风险相关(芬兰aHR 0.20,瑞典aHR 0.35)。
  • 抗精神病药联合治疗与第二或第三低的SUD发生风险相关(瑞典aHR 0.54,芬兰aHR 0.47)。
  • 氯喹平、联合治疗和长效针剂与最低的精神科及SUD相关入院风险相关。

核心结论

  • 氯喹平和抗精神病药联合治疗与精神分裂症患者SUD发生风险降低及双重诊断患者复发率降低关联最强。
  • 两国队列结果一致。

研究设计与样本

  • 两项独立全国队列纳入所有诊断为精神分裂症者(N=45 476),芬兰随访22年(1996-2017),瑞典随访11年(2006-2016)。
  • 使用Cox回归和调整风险比(aHR),个体间模型计算SUD发生风险,个体内模型计算精神科和SUD相关入院风险。

主要发现

  • 无SUD患者中,氯喹平使用与最低的首次SUD发生风险相关(芬兰aHR 0.20,95%CI 0.16-0.24,P<0.001;瑞典aHR 0.35,95%CI 0.24-0.50,P<0.001)。
  • 抗精神病药联合治疗与第二低风险相关(瑞典aHR 0.54,95%CI 0.44-0.66),在芬兰与第三低风险相关(aHR 0.47,95%CI 0.42-0.53)。
  • 两国中,氯喹平、抗精神病药联合治疗和长效针剂与最低的精神科入院和SUD相关入院风险相关。

关键数值与推荐

  • 无SUD患者中,氯喹平 vs 未使用:芬兰aHR 0.20(95%CI 0.16-0.24,P<0.001),瑞典aHR 0.35(95%CI 0.24-0.50,P<0.001)。
  • 抗精神病药联合治疗 vs 未使用:瑞典aHR 0.54(95%CI 0.44-0.66),芬兰aHR 0.47(95%CI 0.42-0.53)。

临床怎么用

  • 在精神分裂症患者中,氯喹平和抗精神病药联合治疗与降低SUD发生风险及复发风险相关。
  • 长效针剂与降低精神科和SUD相关入院风险相关。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Research on the effectiveness of pharmacotherapies for schizophrenia and comorbid substance use disorder (SUD) is very sparse, and non-existent on the prevention of the development of SUDs in patients with schizophrenia. AIMS: To compare the real-world effectiveness of antipsychotics in schizophrenia in decreasing risk of developing an initial SUD, and psychiatric hospital admission and SUD-related hospital admission among patients with an SUD. METHOD: Two independent national cohorts including all persons diagnosed with schizophrenia (N = 45 476) were followed up for 22 (Finland: 1996-2017) and 11 (Sweden: 2006-2016) years. Risk of developing an SUD was calculated with between-individual models, and risks of psychiatric and SUD-related hospital admission were calculated with within-individual models, using Cox regression and adjusted hazard ratios (aHRs) for using versus not using certain antipsychotics. RESULTS: For patients with schizophrenia without an SUD, clozapine use (Finland: aHR 0.20, 95% CI 0.16-0.24, P < 0.001; Sweden: aHR 0.35, 95% CI 0.24-0.50, P < 0.001) was associated with lowest risk of developing an initial SUD in both countries. Antipsychotic polytherapy was associated with second lowest risk (aHR 0.54, 95% CI 0.44-0.66) in Sweden, and third lowest risk (aHR 0.47, 95% CI 0.42-0.53) in Finland. Risk of relapse (psychiatric hospital admission and SUD-related hospital admission) were lowest for clozapine, antipsychotic polytherapy and long-acting injectables in both countries. Results were consistent across both countries. CONCLUSIONS: Clozapine and antipsychotic polytherapy are most strongly associated with reduced risk of developing SUDs among patients with schizophrenia, and with lower relapse rates among patients with both diagnoses.

来源:Br J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Lähteenvuo M, Luykx JJ, Taipale H, et al. Associations between antipsychotic use, substance use and relapse risk in patients with schizophrenia: real-world evidence from two national cohorts. Br J Psychiatry. 2022. PMID: 36004532. doi:10.1192/bjp.2022.117

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。